Fatal attraction: why breast cancer cells home to bone
Open Access
- 25 January 2008
- journal article
- editorial
- Published by Springer Nature in Breast Cancer Research
- Vol. 10 (1) , 101
Abstract
Osteolytic metastases due to breast cancer are serious events. The interactions between breast cancer cells with the microenvironment of bone have been thought to provide an ideal milieu for cancer cells. Recent data now indicate that migration of breast cancer cells into bone and their subsequent growth into metastases depends upon the interaction of the receptor activator of NF-κB ligand (RANKL) with its receptor RANK.Keywords
This publication has 10 references indexed in Scilit:
- Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone MetastasesJournal of Clinical Oncology, 2007
- Regulation of cancer cell migration and bone metastasis by RANKLNature, 2006
- Denosumab in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2006
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.2001
- The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland DevelopmentCell, 2000
- Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1Endocrinology, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature, 1997
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997